Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

LYT-200

Generic Name: LYT-200

Drug Type: Biotech

Overview

LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.

Background

LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Phase 1

Recruiting

Posted: 2023/04/25

Sponsor:PureTech

ID:NCT05829226

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Posted: 2020/12/14

Sponsor:PureTech

ID:NCT04666688

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape

2 months ago

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

BioNTech Advances Oncology Pipeline with BNT327/PM8002 and mRNA Immunotherapies

4 months ago

BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.

FDA Grants Fast Track Designation to PureTech's LYT-200 for Acute Myeloid Leukemia

4 months ago

The FDA has granted Fast Track designation to LYT-200, PureTech's anti-galectin-9 monoclonal antibody, for treating acute myeloid leukemia (AML).

Cell Therapy and Targeted Therapies Dominate Oncology Advances in Early 2025

7 months ago

The FDA issued a CRL for Atara Biotherapeutics' tabelecleucel due to third-party manufacturing issues, not efficacy or safety data, delaying potential approval for EBV+ PTLD.

FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors

8 months ago

The FDA has approved Cobenfy (xanomeline and trospium chloride) as the first new class of drug for schizophrenia in over 30 years, offering a novel approach to treatment.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy